BMO Capital Maintains Outperform on AMN Healthcare Services, Raises Price Target to $40
BMO Capital analyst Jeffrey Silber maintains AMN Healthcare Services (NYSE:AMN) with a Outperform and raises the price target from $38 to $40.
Stocks · News reference
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings came out
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
AMN Healthcare Services expects Q3 nurse and allied staffing revenues to grow 9-11% driven by strong healthcare demand and expanding Managed Services Programs (MSPs) which now represent 46% of consolidated revenues. The company is diversifying through AI-enabled platforms and recent acquisitions. However, competitive pressures, declining language services revenues, and regulatory challenges pose risks to growth.
Citizens Maintains Market Outperform on AMN Healthcare Services, Raises Price Target to $40
Citizens analyst Constantine Davides maintains AMN Healthcare Services (NYSE:AMN) with a Market Outperform and raises the price target from $36 to $40.
UBS Maintains Neutral on AMN Healthcare Services, Raises Price Target to $35
UBS analyst A.J. Rice maintains AMN Healthcare Services (NYSE:AMN) with a Neutral and raises the price target from $32 to $35.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. (ARDX)
A securities class action lawsuit has been filed against Ardelyx, Inc. for allegedly providing misleading statements about its commercial performance while concealing material adverse facts regarding payer access barriers and reimbursement issues for XPHOZAH and IBSRELA. The company reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, causing the stock to decline approximately 18% in a single day.
Ardelyx Q2 2026 Earnings Call Transcript
Ardelyx (NASDAQ:ARDX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to